Tags

Type your tag names separated by a space and hit enter

New therapeutic approaches for hot flashes in women.

Abstract

While most women will suffer from hot flashes at some point over their lifetime, most symptoms resolve with time. However, some women may experience severe and/or long-lasting hot flashes. Estrogen, the most effective treatment for hot flashes, is not generally recommended for women with a history of breast cancer or women at high risk of developing breast cancer. Moreover, long-term administration of estrogen to healthy women is associated with increased risks of cardiovascular disease, stroke, and breast cancer. Newer antidepressants from the selective serotonin or noradrenergic reuptake inhibitor family, such as venlafaxine and paroxetine, appear to be among the most effective nonhormonal agents for the treatment of hot flashes. New information demonstrates that gabapentin also is an effective nonhormonal therapy for hot flashes. In this review, we will discuss current knowledge of the epidemiology and pathophysiology of hot flashes, along with treatment options. We will focus on nonhormonal treatments that have been studied in prospective randomized clinical trials, and will present an algorithm for the treatment of symptomatic patients.

Authors+Show Affiliations

,

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231-1000, USA. vstearn1@jhmi.edu

Source

The journal of supportive oncology 1:1 pg 11-21; discussion 14-5, 19-21

MeSH

Aged
Aging
Antidepressive Agents
Complementary Therapies
Female
Hormone Replacement Therapy
Hot Flashes
Humans
Incidence
Middle Aged
Randomized Controlled Trials as Topic

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15352639

Citation

Stearns, Vered, and Charles L. Loprinzi. "New Therapeutic Approaches for Hot Flashes in Women." The Journal of Supportive Oncology, vol. 1, no. 1, 2003, pp. 11-21; discussion 14-5, 19-21.
Stearns V, Loprinzi CL. New therapeutic approaches for hot flashes in women. J Support Oncol. 2003;1(1):11-21; discussion 14-5, 19-21.
Stearns, V., & Loprinzi, C. L. (2003). New therapeutic approaches for hot flashes in women. The Journal of Supportive Oncology, 1(1), pp. 11-21; discussion 14-5, 19-21.
Stearns V, Loprinzi CL. New Therapeutic Approaches for Hot Flashes in Women. J Support Oncol. 2003;1(1):11-21; discussion 14-5, 19-21. PubMed PMID: 15352639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New therapeutic approaches for hot flashes in women. AU - Stearns,Vered, AU - Loprinzi,Charles L, PY - 2004/9/9/pubmed PY - 2004/9/24/medline PY - 2004/9/9/entrez SP - 11-21; discussion 14-5, 19-21 JF - The journal of supportive oncology JO - J Support Oncol VL - 1 IS - 1 N2 - While most women will suffer from hot flashes at some point over their lifetime, most symptoms resolve with time. However, some women may experience severe and/or long-lasting hot flashes. Estrogen, the most effective treatment for hot flashes, is not generally recommended for women with a history of breast cancer or women at high risk of developing breast cancer. Moreover, long-term administration of estrogen to healthy women is associated with increased risks of cardiovascular disease, stroke, and breast cancer. Newer antidepressants from the selective serotonin or noradrenergic reuptake inhibitor family, such as venlafaxine and paroxetine, appear to be among the most effective nonhormonal agents for the treatment of hot flashes. New information demonstrates that gabapentin also is an effective nonhormonal therapy for hot flashes. In this review, we will discuss current knowledge of the epidemiology and pathophysiology of hot flashes, along with treatment options. We will focus on nonhormonal treatments that have been studied in prospective randomized clinical trials, and will present an algorithm for the treatment of symptomatic patients. SN - 1544-6794 UR - https://www.unboundmedicine.com/medline/citation/15352639/New_therapeutic_approaches_for_hot_flashes_in_women_ L2 - https://medlineplus.gov/hormonereplacementtherapy.html DB - PRIME DP - Unbound Medicine ER -